Restricted accessResearch articleFirst published online 2017-07
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient
Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF). Tenofovir alafenamide fumarate (TAF) is a novel prodrug with less nephrotoxicity. We report resolution of Fanconi syndrome in a HIV and hepatitis B coinfected patient switched from TDF to TAF.
Get full access to this article
View all access options for this article.
References
1.
GraceyDM, SnellingP, McKenzieP, StrasserSI: Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther, 2013; 18:945–948.
2.
de Vries-SluijsTE, ReijndersJG, HansenBE, ZaaijerHL, PrinsJM, PasSD, SchuttenM, HoepelmanAI, RichterC, MulderJW, de ManRA, JanssenHL, van der EndeME: Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology, 2010; 139:1934–1941.
Rodriguez-NovoaS, LabargaP, D'AvolioA, BarreiroP, AlbalateM, VispoE, SoleraC, SiccardiM, BonoraS, Di PerriG, SorianoV: Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS, 2010; 24:1064–1066.
5.
MarkowitzM, ZolopaA, SquiresK, RuaneP, CoakleyD, KearneyB, ZhongL, WulfsohnM, MillerMD, LeeWA: Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother, 2014; 69:1362–1369.
6.
SaxPE, WohlD, YinMT, PostF, DeJesusE, SaagM, PozniakA, ThompsonM, PodzamczerD, MolinaJM, OkaS, KoenigE, TrottierB, Andrade-VillanuevaJ, CrofootG, CustodioJM, PlummerA, ZhongL, CaoH, MartinH, CallebautC, ChengAK, FordyceMW, McCallisterS: Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet, 2015; 385:2606–2615.
7.
PozniakA, ArribasJR, GatheJ, GuptaSK, PostFA, BlochM, AvihingsanonA, CrofootG, BensonP, LichtensteinK, RamgopalM, ChetchotisakdP, CustodioJM, AbramME, WeiX, ChengA, McCallisterS, SenGuptaD, FordyceMW: Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-Week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr, 2016; 71:530–537.
8.
BamRA, YantSR, CihlarT: Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther, 2014; 19:687–692.
9.
PostFA, TebasP, ClarkeA, CotteL, ShortWR, AbramME, JiangS, ChengA, DasM, FordyceM: Brief report: Switching to tenofovir alafenamide, co-formulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96 week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr, 2017; 74:180–184.
10.
MikulaJM, ManionMM, MaldarelliF, SuarezLM, Norman-WheelerJF, OberAG, DewarRL, KoppJB, LaneHC, PauAK: Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir DF-associated renal tubulopathy. Antivir Ther, 2016; 21:553–558.
11.
GarciaM, Le MoalG, GodetC, BeraudG, Chagneau-DerrodeC, RoblotF: First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome. AIDS, 2016; 30:1487–1488.
12.
ButiM, SetoWK, ChanH, ChuangW, StepanovaT, HuiA, LimY, MehtaR, JanssenH, AcharyaS, FlahertyJ, MassettoB, CathcartA, DinhP, SubramanianG, McHutchinsonJ, PanC, BrunettoM, IzumiN, MarcellinP: A phase 3 study of tenofovir alafenamide compared with tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: Week 48 efficacy and safety fesults. EASL, April22–24, 2016, Barcelona, Spain, 2016.
13.
GallantJ, BrunettaJ, CrofootG, BensonP, MillsA, BrinsonC, ChengA, GarnerW, FordyceM, DasM, McCallisterS: Efficacy and safety of switching to simpler single-tablet of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-1/hepatitis B coinfected adults in North America and Japan (NCT02071082) week 48 results. IAS 2015, July19–23, Vancouver, British Columbia, 2015.
